Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PSMA-DC: 177Lu-vipivotide tetraxetan versus observation in PSMA-positive oligometastatic prostate cancer
CTR20243344Phase 3Active
- Sponsor
- Novartis
- Start
- Aug 2026
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in prostate cancer (PCa) comparing lutetium Lu 177 vipivotide tetraxetan arm with observation arm (2 arms). Primary endpoint: Metastasis-free survival. Started Aug 2026; status: active.
02
Drugs
lutetium lu 177 vipivotide tetraxetan
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on CTR20243344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243344.